Argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

MLA

“Argenx Reports Positive Topline Results from Phase 2 Proof-of-Concept Trial of Efgartigimod in Primary Immune Thrombocytopenia.” Plus Company Updates, 19 Sept. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.554894708&authtype=sso&custid=ns315887.

APA

Argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia. (2018, September 19). Plus Company Updates.

Chicago

Plus Company Updates. 2018. “Argenx Reports Positive Topline Results from Phase 2 Proof-of-Concept Trial of Efgartigimod in Primary Immune Thrombocytopenia,” September 19. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.554894708&authtype=sso&custid=ns315887.